Community Health Systems, Inc. (CYH)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-06. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 36/100 (MEDIUM), 23.5 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 16.3% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Can Community Health Sustain Growth as Elective Demand Softens?
- Zacks Industry Outlook Tenet, Acadia and Community Health Systems
- Community Health Systems to Participate in the Wells Fargo 21st Annual Healthcare Conference
- Community Health Systems (CYH) Up 7.2% Since Last Earnings Report: Can It Continue?
- Community Health Systems Inc (CYH) Q2 2026 Earnings Call Highlights: Navigating Revenue ...
- Community Health Systems (CYH) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
- Community Health Systems (CYH) Reports Q2 Loss, Lags Revenue Estimates
- Community Health Systems, Inc. Announces Second Quarter Ended June 30, 2026 Results
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Community Health Systems, Inc..
Full CYH Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.